Eli Lilly CFO: Weight-loss drug demand will outstrip GLP-1 supply through 2024

shares were down slightly Tuesday despite reporting better-than-expected earnings on both the top and bottom lines for the final quarter of 2023, driven by an expected boost from GLP-1 products Mounjaro and Zepbound. The company is trading at $705 per share, after popping in pre-market trading on…#glp1 #mounjaro #zepbound #lilly #davidricks #ricks #novonordisk #nvo #elililly #anatashkenazi
Source: Reuters: Health - Category: Consumer Health News Source Type: news